Hikma Pharmaceuticals (H5P) Stock Overview
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
H5P Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£18.14 |
| 52 Week High | UK£23.40 |
| 52 Week Low | UK£13.80 |
| Beta | 0.65 |
| 1 Month Change | 7.40% |
| 3 Month Change | 22.15% |
| 1 Year Change | -21.13% |
| 3 Year Change | -16.79% |
| 5 Year Change | -40.72% |
| Change since IPO | 345.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| H5P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.5% | 6.1% | 4.1% |
| 1Y | -21.1% | 57.0% | 2.9% |
Return vs Industry: H5P underperformed the German Pharmaceuticals industry which returned 57% over the past year.
Return vs Market: H5P underperformed the German Market which returned 2.9% over the past year.
Price Volatility
| H5P volatility | |
|---|---|
| H5P Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: H5P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: H5P's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,400 | Said Samih Darwazah | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| H5P fundamental statistics | |
|---|---|
| Market cap | €3.85b |
| Earnings (TTM) | €351.59m |
| Revenue (TTM) | €2.93b |
Is H5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H5P income statement (TTM) | |
|---|---|
| Revenue | US$3.35b |
| Cost of Revenue | US$1.89b |
| Gross Profit | US$1.46b |
| Other Expenses | US$1.06b |
| Earnings | US$402.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 1.89 |
| Gross Margin | 43.51% |
| Net Profit Margin | 12.00% |
| Debt/Equity Ratio | 59.5% |
How did H5P perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 18:55 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| James Gordon | Barclays |
| Beatrice Fairbairn | Berenberg |